Suppr超能文献

包裹呼吸道合胞病毒M蛋白和M2蛋白的病毒样颗粒可诱导强烈的T细胞反应。

Viruslike Particles Encapsidating Respiratory Syncytial Virus M and M2 Proteins Induce Robust T Cell Responses.

作者信息

Schwarz Benjamin, Morabito Kaitlyn M, Ruckwardt Tracy J, Patterson Dustin P, Avera John, Miettinen Heini M, Graham Barney S, Douglas Trevor

机构信息

Department of Chemistry, Indiana University, 800 East Kirkwood Avenue, Bloomington, Indiana 47405, United States.

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.

出版信息

ACS Biomater Sci Eng. 2016;2(12):2324-2332. doi: 10.1021/acsbiomaterials.6b00532. Epub 2016 Nov 3.

Abstract

Subunit vaccines provide a safe, focused alternative to conventional vaccines. However, these vaccines often require significant adjuvants and are particularly hard to target toward cytotoxic T lymphocyte (CTL) immunity. Viruslike particles (VLPs) provide biomaterial scaffolds with pathogen-like polyvalent structures making them useful platforms for biomimetic antigen delivery to the immune system. Encapsidation of antigens within VLPs has been shown to enhance antigen availability for CD8 T cell responses. Here, we examine the potential to generate complex responses to multiple subunit antigens localized within the same VLP particle. Two proteins of respiratory syncytial virus (RSV) with well-characterized CD8 T cell responses, the matrix (M) and matrix 2 (M2) proteins, were successfully coencapsidated within the P22 VLP. Upon intranasal administration in mice, the particles stimulated CD8 T cell memory responses against both antigens. In addition, vaccination elicited tissue-resident T cell populations. Upon subsequent RSV challenge, P22-M/M2-treated mice displayed significantly reduced lung viral titers. This demonstrates the utility of the P22 VLP in directing immune responses to multiple encapsidated viral antigens, demonstrating the potential of this technology to facilitate immunity to multiple targets simultaneously.

摘要

亚单位疫苗为传统疫苗提供了一种安全、有针对性的替代方案。然而,这些疫苗通常需要大量佐剂,并且特别难以靶向细胞毒性T淋巴细胞(CTL)免疫。病毒样颗粒(VLP)提供了具有病原体样多价结构的生物材料支架,使其成为向免疫系统进行仿生抗原递送的有用平台。已证明将抗原包裹在VLP内可提高CD8 T细胞反应中抗原的可用性。在这里,我们研究了对位于同一VLP颗粒内的多种亚单位抗原产生复杂反应的潜力。呼吸道合胞病毒(RSV)的两种具有明确CD8 T细胞反应的蛋白质,即基质(M)蛋白和基质2(M2)蛋白,成功地共同包裹在P22 VLP内。在小鼠鼻内给药后,这些颗粒刺激了针对两种抗原的CD8 T细胞记忆反应。此外,疫苗接种引发了组织驻留T细胞群体。在随后的RSV攻击后,经P22-M/M2处理的小鼠的肺病毒滴度显著降低。这证明了P22 VLP在引导对多种包裹的病毒抗原的免疫反应中的效用,证明了该技术同时促进对多个靶标的免疫的潜力。

相似文献

引用本文的文献

5
Engineering customized nanovaccines for enhanced cancer immunotherapy.工程定制纳米疫苗以增强癌症免疫治疗
Bioact Mater. 2024 Mar 10;36:330-357. doi: 10.1016/j.bioactmat.2024.02.028. eCollection 2024 Jun.
9
Assessing the generation of tissue resident memory T cells by vaccines.评估疫苗产生组织驻留记忆 T 细胞的能力。
Nat Rev Immunol. 2023 Oct;23(10):655-665. doi: 10.1038/s41577-023-00853-1. Epub 2023 Mar 31.
10

本文引用的文献

3
Virus-based nanoparticles as platform technologies for modern vaccines.基于病毒的纳米颗粒作为现代疫苗的平台技术。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Jul;8(4):554-78. doi: 10.1002/wnan.1383. Epub 2016 Jan 19.
5
Development of virus-like particles for diagnostic and prophylactic biomedical applications.用于诊断和预防性生物医学应用的病毒样颗粒的开发。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 Sep-Oct;7(5):722-35. doi: 10.1002/wnan.1336. Epub 2015 Feb 13.
10
Bioengineering virus-like particles as vaccines.生物工程病毒样颗粒作为疫苗。
Biotechnol Bioeng. 2014 Mar;111(3):425-40. doi: 10.1002/bit.25159. Epub 2013 Dec 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验